Therefore, modulation of neurogenic inflammation through inhibition of the SP pathway using NK1 tachykinin receptor antagonists may provide a novel approach to the management of cerebral oedema following stroke and other forms of acute brain injury. The gene discussed is TFF2; the disease is injury.